Medpace Holdings, Inc. (MEDP) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $520.00. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MEDP = $350.17 (-32.7% from the current price, the stock appears overvalued). Analyst consensus target is MEDP = $534 (+2.7% upside).
Valuation: MEDP trades at a trailing Price-to-Earnings (P/E) of 31.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.86.
Financials: revenue is $2.5B, +20.3%/yr average growth. Net income is $451M, growing at +23.3%/yr. Net profit margin is 17.8% (healthy). Gross margin is 30.1% (+0.5 pp trend).
Balance sheet: total debt is $250M against $459M equity (Debt-to-Equity (D/E) ratio 0.55, moderate). Current ratio is 0.74 (tight liquidity). Debt-to-assets is 12.7%. Total assets: $2.0B.
Analyst outlook: 4 / 17 analysts rate MEDP as buy (24%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 39/100 (Fail), Growth 100/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 62/100 (Partial), Future 34/100 (Fail), Income 70/100 (Pass).
